Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$16.70
+2.2%		$18.84
$5.95
▼
$62.75
$1.42B1.061.48 million shs799,946 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-0.06%-1.51%-16.97%-4.16%-69.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$16.70
+2.2%		$18.84
$5.95
▼
$62.75
$1.42B1.061.48 million shs799,946 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-0.06%-1.51%-16.97%-4.16%-69.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00
N/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.41
Hold$24.5747.12% Upside

Current Analyst Ratings Breakdown

Latest MLTX and IMGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $50.00
8/7/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/20/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
7/1/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$24.00 ➝ $29.00
6/9/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$30.00
6/8/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$287.61M28.91N/AN/A$0.71 per share43.99
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$4.27 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.84N/AN/AN/AN/A-82.53%-58.17%11/4/2026 (Estimated)

Latest MLTX and IMGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.9086-$0.84+$0.0686-$0.84N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.13
5.70
5.65
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.23
12.56
12.56

Institutional Ownership

CompanyInstitutional Ownership
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
90.50%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%

Insider Ownership

CompanyInsider Ownership
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
5.07%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
277266.26 million252.76 millionNo Data
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
285.11 million76.26 millionOptionable

Recent News About These Companies

What is HC Wainwright's Forecast for MLTX Q3 Earnings?
August 17 at 1:12 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30965089
HC Wainwright Issues Negative Estimate for MLTX Earnings
August 17 at 1:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-negative-estimate-for-mltx-earnings-2026-08-17/
Dimensional Fund Advisors LP Has $490,000 Position in MoonLake Immunotherapeutics $MLTX
August 16 at 3:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-has-490000-position-in-moonlake-immunotherapeutics-mltx-2026-08-16/
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/moonlake-immunotherapeutics-nasdaqmltx-stock-price-expected-to-rise-hc-wainwright-analyst-says-2026-08-13/
MoonLake Immunotherapeutics Sees Unusually Large Options Volume (NASDAQ:MLTX)
August 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30955479
MoonLake’s psoriatic arthritis drug shows promise in phase 3 trial – retail shrugs off premarket slide, says ‘pipeline is intact’
August 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/moonlake-s-psoriatic-arthritis-drug-shows-promise-in-phase-3-trial-retail-shrugs-off-premarket-slide-says-pipeline-is-intact/ar-AA29M2Fr
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.3% - Time to Sell?
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/moonlake-immunotherapeutics-nasdaqmltx-stock-price-down-53-time-to-sell-2026-08-11/
MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moonlake-immunotherapeutics-q2-loss-narrows-130809814.html
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/moonlake-announces-positive-topline-results-from-the-phase-3-izar-1-trial-of-sonelokimab-in-psoriatic-arthritis-demonstrating-significant-improvements-across-all-clinical-endpoints-and-reports-1036435278
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
August 10, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/08/61084682/moonlakes-psoriatic-arthritis-drug-shows-promise-in-late-stage-study
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down - Here's What Happened
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/moonlake-immunotherapeutics-nasdaqmltx-shares-gap-down-heres-what-happened-2026-08-10/
Traders Buy Large Volume of MoonLake Immunotherapeutics Call Options (NASDAQ:MLTX)
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/traders-buy-large-volume-of-moonlake-immunotherapeutics-call-options-nasdaqmltx-2026-08-10/
MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Earnings Results, Beats Estimates By $0.08 EPS
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/moonlake-immunotherapeutics-nasdaqmltx-releases-earnings-results-beats-estimates-by-008-eps-2026-08-10/
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
August 10, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/moonlakes-psoriatic-arthritis-drug-meets-key-goals-late-stage-trial-2026-08-10/
MoonLake announces positive Phase 3 psoriatic arthritis results
August 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/moonlake-announces-positive-phase-3-psoriatic-arthritis-results?utm_source=marketbeat.com&utm_medium=referral
MoonLake reports positive Phase 3 PsA data and $537 million cash
August 10, 2026  |  quiverquant.comQ
MoonLake Immunotherapeutics GAAP EPS of -$0.84
August 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4629815-moonlake-immunotherapeutics-gaap-eps-of-0_84?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=news?source=MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Hold" from Brokerages
August 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951671
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Analysts
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/moonlake-immunotherapeutics-nasdaqmltx-receives-consensus-recommendation-of-hold-from-analysts-2026-08-10/
Renaissance Technologies LLC Raises Stake in MoonLake Immunotherapeutics $MLTX
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-raises-stake-in-moonlake-immunotherapeutics-mltx-2026-08-06/
Arrowstreet Capital Limited Partnership Acquires New Shares in MoonLake Immunotherapeutics $MLTX
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-arrowstreet-capital-limited-partnership-acquires-new-shares-in-moonlake-immunotherapeutics-mltx-2026-08-06/

New MarketBeat Followers Over Time

Media Sentiment Over Time

ImmunoGen stock logo

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$16.70 +0.36 (+2.22%)
As of 02:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas